Results 61 to 70 of about 28,388 (258)

Plasmepsins as Antimalarial Drug Targets—Then, Now, and the Future

Medicinal Research Reviews, EarlyView.
ABSTRACT Malaria is a devastating disease caused by Plasmodium parasites. Plasmodium parasites express ten cathepsin D‐like aspartyl proteases, called plasmepsins (PMs). These PMs have diverse roles fulfill diverse functions throughout the parasite's lifecycle, though several exhibit functional redundancies. Among them, PMV, PMIV, and PMX are essential
Brad E. Sleebs
wiley   +1 more source

Late INa as a Therapeutic Target: New Strategies, Computational Modelling, Drug Development, and Clinical Translation

Medicinal Research Reviews, EarlyView.
ABSTRACT The Nav1.5 channel, a major isoform of voltage‐gated sodium ion channel, is mainly found in ventricular cardiomyocytes, playing a key role in generating essential cardiac action potentials for normal heart rhythms. Mutations in Nav1.5 have been associated with severe heart conditions such as long QT syndrome, Brugada syndrome, cardiac ...
Arkapravo Chattopadhyay, Lynn C. Lunsonga, Peter E. Light, Khaled Barakat   +3 more
wiley   +1 more source

The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes

Nature Communications
Diabetes is common in patients with chronic obstructive pulmonary disease. Sodium-glucose co-transporter-2 inhibitors are effective in treating type 2 diabetes and provide benefits for conditions like cardiovascular and kidney diseases.
Jheng-Yan Wu, Khai-Chi Hu, Mei-Yuan Liu, Yu-Jou Wu, Wan-Hsuan Hsu, Ya-Wen Tsai, Ting-Hui Liu, Po-Yu Huang, Min-Hsiang Chuang, Tsung Yu, Kuang-Ming Liao, Chih-Cheng Lai   +11 more
doaj   +1 more source

Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetes

World Journal of Diabetes, 2010
The addition of the dipeptidyl peptidase-4 (DDP-4) inhibitor has been reported to achieve greater improvements in glucose metabolism with fewer adverse events compared to increasing the metformin dose in type 2 diabetic patients. We present a patient with steroid-induced diabetes whose blood glucose levels were ameliorated by the use of the DPP-4 ...
Hidekatsu, Yanai, Yoshinori, Masui, Reo, Yoshikawa, Junwa, Kunimatsu, Hiroshi, Kaneko   +4 more
openaire   +2 more sources

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

Obesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu, Hao Dai, Huilin Tang, William T. Donahoo, Thomas J. George, Ramon C. Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D. Licht, John M. Allen, Kelvin P. Lee, Jingchuan Guo, Jiang Bian   +13 more
wiley   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source

Early‐Life Dietary Protein Source Reshapes Gut Microbiota but Fails to Curtail Diet‐Induced Metabolic Syndrome in Young Rats

Obesity, EarlyView.
ABSTRACT Objective Dairy consumption plays a protective role in obesity that may be mediated through the gut microbiota. This study examined the role of dairy proteins, casein, whey, and complete dairy (skim milk powder), and a plant‐based alternative, soy, on gut microbiota composition, obesity susceptibility, and insulin sensitivity in early ...
Chunlong Mu, Micaela Hartslief, Jessica Chong, Shrushti Shah, Jennifer Thompson, Raylene A. Reimer, David C. Wright, Jane Shearer   +7 more
wiley   +1 more source

Dipeptidyl Peptidase‐4 Inhibitor Use and Risk of Pemphigus Vulgaris and Foliaceus: A Retrospective Cohort Study Using Databases of the Korea National Health Insurance Claims and the National Health Screening Examination

The Journal of Dermatology, EarlyView.
ABSTRACT Although population‐based studies have reported an increased risk of bullous pemphigoid and pemphigus associated with dipeptidyl peptidase‐4 (DPP‐4) inhibitors, there is limited, well‐designed epidemiological evidence for pemphigus vulgaris (PV), which has only been supported by case reports thus far.
Jaein Lee, Jae Hyun Bae, Seokyung Hahn
wiley   +1 more source

Hypoglycemic Coma in a Hemodialysis Patient Receiving Blood Glucose-Lowering Therapy With the Single Agent Teneligliptin

Clinical Medicine Insights: Case Reports, 2018
Blood glucose management in patients undergoing dialysis is clinically challenging. In this population, most conventional oral hypoglycemic agents are contraindicated, especially from the perspective of pharmacokinetics. Dipeptidyl peptidase-4 inhibitors
Takumi Minezumi, Shin-ichi Takeda, Yusuke Igarashi, Kentaro Sato, Yoshiaki Murakami, Daisuke Nagata   +5 more
doaj   +1 more source

Use of Glucagon‐Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009–2024

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Diabetes, obesity and bipolar disorder often co‐occur and may have shared pathophysiology. Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) treat diabetes and obesity but their impact on bipolar disorder is unknown. In this era of stagnated pharmacotherapy, we examined psychiatric hospitalisation and absence from work due to ...
Heidi Taipale, Mark Taylor, Markku Lähteenvuo, Ellenor Mittendorfer‐Rutz, Antti Tanskanen, Jari Tiihonen   +5 more
wiley   +1 more source